Inclusion Criteria:  Participants must be 13 years or older Diagnosed with Microcystic Lymphatic Malformations Able and willing to comply with all protocol-required activities Willing and able to provide written informed consent  Exclusion Criteria:  Any significant concurrent condition that could adversely affect participation. Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022 Patient's deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities.